Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Shares Outstanding (Diluted Average) (2020 - 2024)

KalVista Pharmaceuticals' Shares Outstanding (Diluted Average) history spans 3 years, with the latest figure at $46.5 million for Q4 2024.

  • For Q4 2024, Shares Outstanding (Diluted Average) rose 34.72% year-over-year to $46.5 million; the TTM value through Oct 2024 reached $46.5 million, up 34.72%, while the annual FY2024 figure was $36.8 million, N/A changed from the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2024 was $46.5 million at KalVista Pharmaceuticals, roughly flat from $46.2 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $46.5 million in Q4 2024 and bottomed at $17.7 million in Q2 2020.
  • The 3-year median for Shares Outstanding (Diluted Average) is $34.6 million (2024), against an average of $35.8 million.
  • The largest YoY upside for Shares Outstanding (Diluted Average) was 34.72% in 2024 against a maximum downside of 34.34% in 2024.
  • A 3-year view of Shares Outstanding (Diluted Average) shows it stood at $17.7 million in 2020, then surged by 94.32% to $34.5 million in 2023, then soared by 34.72% to $46.5 million in 2024.
  • Per Business Quant, the three most recent readings for KALV's Shares Outstanding (Diluted Average) are $46.5 million (Q4 2024), $46.2 million (Q3 2024), and $36.8 million (Q2 2024).